Trials / Completed
CompletedNCT00407095
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pardoprunox | 12-42 mg/day |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2006-12-04
- Last updated
- 2010-09-13
Locations
87 sites across 13 countries: United States, Albania, Argentina, Brazil, Bulgaria, Canada, Chile, Colombia, Latvia, Lithuania, Peru, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00407095. Inclusion in this directory is not an endorsement.